BerGenBio Logo

BerGenBio

BGBIO | OL

Overview

Corporate Details

ISIN(s):
NO0012921180 (+2 more)
LEI:
213800TYYFXKYF3V2A23
Country:
Norway
Address:
MØLLENDALSBAKKEN 9, 5009 BERGEN
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections. AXL: a promising target to treat life-threatening diseases The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab. Business model: R&D excellence and strategic partnerships BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-05 16:49
Share Issue/Capital Change
BerGenBio ASA - Updated key information related to the rights issue
English 10.0 KB
2025-08-04 13:40
Post-Annual General Meeting Information
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
Norwegian 794.1 KB
2025-08-04 13:40
M&A Activity
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
English 2.2 KB
2025-07-03 14:53
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
Norwegian 441.1 KB
2025-07-03 14:53
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
English 2.6 KB
2025-06-30 22:30
Share Issue/Capital Change
BerGenBio ASA - Key information related to the rights issue
English 10.0 KB
2025-06-30 22:05
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
English 101.2 KB
2025-06-30 22:05
Share Issue/Capital Change
Announcement of fully underwritten rights issue
English 21.0 KB
2025-06-30 22:00
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
English 19.5 KB
2025-06-26 11:29
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
Norwegian 419.9 KB
2025-06-26 11:29
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025
English 1.1 KB
2025-06-03 19:22
M&A Activity
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
English 2.6 KB
2025-06-03 15:55
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
Norwegian 424.8 KB
2025-06-03 15:55
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting
English 2.6 KB
2025-04-30 07:51
Report Publication Announcement
Financial calendar
English 666 bytes

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies